Home | Sitemap | Search | ContactA- A A+
   
 
    Public Member Support us  
 
Home > News > Trial News

Trial News 

19.02.2019 

Clinical Trials

IBCSG 23-01 NEJM Journal Watch - Summary and Comment
Omission of Axillary Dissection for Minimal Node-Positive Breast Cancer
William J. Gradishar, MD reviewing Galimberti V et al. Lancet Oncol 2018 Sep 5  


04.06.2018
TEXT & SOFT Press Release ASCO 2018

Ovarian Suppression Reduces Recurrence and Can Improve Survival in Young Breast Cancer Patients

SOFT TEXT PRESS RELEASE 2018 June.pdf

Publications:                

371. Loi S, Giobbie-Hurder A, Gombos A, Bachelot T, Hui R, Curigliano G, Campone M, Biganzoli L, Bonnefoi H, Jerusalem G, Bartsch R, Rabaglio-Poretti M, Kammler R, Maibach R, Smyth MJ, Di Leo A, Colleoni M, Viale G, Regan MM, André F. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multi-centre, phase 1b-2 trial. Lancet Oncol. doi: 10.1016/S1470-2045(18)30812-X. 2019 February 11. [Epub ahead of print] (IBCSG 45-13) (Journal Impact Factor 36.418).

The manuscript is attached and The Lancet Oncology link is here: https://doi.org/10.1016/S1470-2045(18)30812-X

370. Dellapasqua S, Gray KP, Munzone E, Rubino D, Gianni L, Johansson H, Viale G, Ribi K, Bernhard J, Kammler R, Maibach R, Rabaglio-Poretti M, Ruepp B, Di Leo A, Coates AS, Gelber RD, Regan MM, Goldhirsch A, Colleoni M; International Breast Cancer Study Group. Neoadjuvant degarelix versus triptorelin in premenopausal patients who receive letrozole for locally advanced endocrine-responsive breast cancer: A randomized phase II trial. J Clin Oncol. doi: 10.1200/JCO.18.00296. 2018 Dec 27. [Epub ahead of print] (IBCSG 41-13) (Journal Impact Factor 26.303).

369. Ruhstaller T, Giobbie-Hurder A, Colleoni M, Jensen MB, Ejlertsen B, de Azambuja E, Neven P, Láng I, Jakobsen EH, Gladieff L, Bonnefoi H, Harvey VJ, Spazzapan S, Tondini C, Del Mastro L, Veyret C, Simoncini E, Gianni L, Rochlitz C, Kralidis E, Zaman K, Jassem J, Piccart-Gebhart M, Di Leo A, Gelber RD, Coates AS, Goldhirsch A, Thürlimann B, Regan MM; members of the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group. Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial. J Clin Oncol. doi: 10.1200/JCO.18.0044. 2018 Nov 26. [Epub ahead of print] (BIG 1-98) (Journal Impact Factor 26.303).

News

16.06.2019:
33. SCHWEIZER FRAUENLAUF 16. Juni 2019 woman 4 woman - walking together, stronger than ever

23.03.2019:
The next IBCSG Annual Meeting will take place in Vienna Austria on March 23 and 24, 2019.       

20.02.2019:
New publications are available 

All News

 
  Print